Phase 3 Zilebesiran Trial in Hypertension Now Recruiting
A Phase 3 trial of zilebesiran in hypertension patients with cardiovascular disease or high risk is recruiting as of September 18, 2026.
Read Full ArticleAll News
Dulaglutide Comparator Trial NCT06779929 Marked Completed
A trial comparing tirzepatide to dulaglutide or semaglutide on major cardiovascular events in type 2 diabetes was marked completed on 2026-09-18.
Trial Update: GLP-1 RA Plus SOC Study Recruiting for Metastatic Cancers
An early phase 1 trial testing a GLP-1 receptor agonist plus standard of care in metastatic pancreatic, colorectal, or HCC is now recruiting as of Sept 18, 2026.
Gonadorelin-Related Trial NCT05161195 Now Active, Not Recruiting
Phase 4 rollover trial for continued access to ribociclib, listed under NCT05161195, is active but not recruiting as of Sept 18, 2026.
Goserelin-Linked Trial NCT03701334 Update: Phase 3 Status Active, Not Recruiting
A Phase 3 trial evaluating ribociclib with endocrine therapy, including goserelin, in HR+/HER2- early breast cancer was updated on Sep 18, 2026.
Kisspeptin-Related Trial NCT07169136 Recruiting on GLP-1 in PCOS Adolescents
A trial examining GLP-1 agonist effects on neuro-reproductive function, including kisspeptin pathways, in obese adolescent females with PCOS is recruiting as of Sept 18, 2026.
Leptin Trial NCT05437809 Now Active, Not Recruiting as of Sept 2026
Trial update for leptin: "Biobehavioral Reward Responses..." study status changed to active, not recruiting, dated September 18, 2026.
Leuprolide Featured in Phase 2 SPARKLE Trial, Now Recruiting
A Phase 2 trial (NCT07650240) testing PSMA-targeted therapy with androgen receptor suppression via leuprolide began recruiting as of September 18, 2026.
Nesiritide Trial "MR Evidence of Cardiac Inflammation Post-Stroke" Recruiting
Trial update dated Sept 18, 2026: study NCT05714618 involving nesiritide, "MR Evidence of Cardiac Inflammation Post-Stroke," is listed as recruiting.
Semaglutide Trial on Weight Trajectories in Grade 3 Obesity Registered
A new trial, NCT07423481, will study weight trajectories and predictive factors after semaglutide in patients with grade 3 and complicated obesity. Status: not yet recruiting.
Somatostatin-Related Trial NCT04234568 Now Active, Not Recruiting
Phase 1 trial testing Triapine added to Lutetium Lu 177 Dotatate for neuroendocrine tumors is active but not recruiting, per a September 18, 2026 update.
Trial Update: NCT06317649 Phase 2 AML Study Recruiting as of Sep 2026
A Phase 2 MyeloMATCH trial testing venetoclax and HMA in older, unfit FLT3-mutated AML patients is recruiting, per a Sep 18, 2026 update.
Phase 3 Tirzepatide Trial for Post-Bariatric Weight Loss Registered
A Phase 3 trial testing tirzepatide for suboptimal weight loss after bariatric surgery was registered on Sep 18, 2026, and is not yet recruiting.
Phase 2 Trial "tVNS in SLE" Recruiting as of Sept 2026
A Phase 2 trial titled Transcutaneous Vagus Nerve Stimulation in SLE is recruiting as of September 17, 2026, per ClinicalTrials.gov.
Trial Update: Acetyl L-Carnitine Study Marked Completed (NCT07660081)
A trial examining Acetyl L-Carnitine supplementation in obese, diabetic, postmenopausal women with osteoarthritis has been marked completed as of Sept 17, 2026.
Mazdutide Phase 4 Trial for Obesity, Gout Registered, Not Yet Recruiting
A Phase 4 trial of mazdutide for weight management and gout in adults with obesity was listed on Sep 17, 2026, with recruitment not yet started.
Phase 1 Trial of Lutetium Lu 177 Edotreotide in Pediatric SSTR Tumors Recruiting
A Phase 1 trial evaluating Lutetium Lu 177 edotreotide dosing, PK, and safety in pediatric SSTR-positive tumors is recruiting as of September 17, 2026.
Trial Update: Oxytocin-Related Study on IV Papaverine for PROM Recruiting
A trial titled Intravenous Papaverine for Term Prelabor Rupture of Membranes is recruiting as of Sep 17, 2026, per ClinicalTrials.gov.
Pasireotide Phase 2 Trial for Post-Bariatric Hypoglycaemia Now Active, Not Recruiting
A Phase 2 trial of subcutaneous pasireotide in post-bariatric hypoglycaemia patients updated status to active, not recruiting, as of Sep 17, 2026.
Phase 3 Trial Involving Lanreotide Comparator Now Recruiting
A Phase 3 trial, "Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors," is recruiting as of Sept 16, 2026.
Exenatide Trial "Cardiac Parameters and Mesenteric Blood Flow" Completed
Trial NCT01988545 studying exenatide's effect on cardiac parameters and mesenteric blood flow is now listed as completed as of Sept 15, 2026.